Cannabis Has The Potential To Possibly Stop Diabetes
In San Francisco's Bay Area, researchers have found a process to increase production on one of the rarest cannabinoids found in the cannabis, THCV
THCV stands for tetrahydrocannabivarin and is only found in trace amounts in most cannabis strains. Yet, the compound, according to scientists, might provide treatments for diabetes, lower cholesterol, and provide an array of other medicinal benefits.
Dr. Michael Moskowitz, the founder of the Medical Cannabis Research Consortium of Marin, who has been studying THCV, told Mercury News “The only thing that THCV does is it’s analgesic and anti-inflammatory, it’s neuroprotective, which means it protects the nervous system,” Moskowitz said. “It’s anti-nausea and vomiting. It helps with bone health and bone formation, it’s sleep-promoting, it’s anti-epileptic, it’s anti-anxiety. It’s a major anti-psychotic. And it helps with appetite suppression, it’s anti-diabetic and it’s anti-cholesterol. Other than that it didn’t do that much."
Cannabis strains with higher THCV properties are thought to have come from Sub-Saharan plants. Due to a lack of understanding and desire for cannabis that would produce the largest “high” in users, growers were mainly breeding strains that had higher THC levels, thus not neglecting other cannabinoids.
Other researchers in the Bay Area believe that THCV has the potential to become as popular as CBD. Whether or not THCV is psychoactive like THC, remains inconclusive. According to Moskowitz, it has been labeled as both psychoactive and not.
The researchers have plans to directly compete with GW Pharmaceuticals, the company behind Epidiolex, the first cannabis-based pharmaceutical approved by the FDA.
Mercury News stated, GW Pharmaceuticals “has also been researching THCV as a potential treatment for a variety of diseases and health issues such type II diabetes, schizophrenia, epilepsy, cognitive disorders such as Alzheimer’s, along with several others.”